Pipeline
Descubra mais sobre nosso pipeline de P&D e estudos em andamento abaixo
Programas de desenvolvimento – Tumor sólido
Medicamento
Indicação
Fase 1
Fase 2
Fase 3
Tislelizumabe
(PD-1 mAb)
1L NonSq NSCLC
1L Sq NSCLC
2/3L NSCLC
CPCNP neo/adjuvante
1L CPPC-EE
1L ESCC
2L ESCC
LA ESCC
1L GC/GEJC
1L CNF
1L HCC
1L UBC
2/3L HCC
1L NSCLC (subcutaneous formulation)
Ociperlimabe
(TIGIT mAb)
1L CPCNP com PD-L1 alto
NSCLC dose confirmation
BG-685011
(Inibidor de CDK2)
BC e tumores sólidos
BGB-43395
(Inibidor de CDK4)
BC e tumores sólidos
BG-C90742
(B7H4 ADC)
BC e tumores sólidos
BGB-C354
(B7H3 ADC)
Tumores sólidos
LBL-0073
(LAG3 mAb)
MSS-CCR
1L ESCC
Umbrellaa
(combinações de IO)
1L NSCLC
CPCNP neo/adjuvante
2L+ CPCNP
1L CECP
Zanidatamabe4
(HER2 BsAb)
2L CTB HER2+
1L AGE HER2+
BGB-A445
(OX40 mAb)
Melanoma, UC
BGB-15025
(Inibidor de HPK1)
Tumores sólidos
BGB-26808
(Inibidor de HPK1)
Tumores sólidos
BGB-24714
(SMAC mimético)
Tumores sólidos
BGB-30813
(inibidor de DGKζ)
Tumores sólidos
BGB-A3055
(CCR8 mAb)
Tumores sólidos
Pamiparibe
(inibidor de PARP 1/2)
2L MTx PSOC gBRCAm
Tarlatamabe5
(DLL3 x CD3 BsAb)
2L CPPC
1L CPPC-EE
LS-SCLC
3L+ CPPC
Xaluritamig5
(STEAP1 x CD3 BsAb)
mCRPC
BGB-R046
(IL-15 prodrug)
Tumores sólidos
BGB-B3227
(MUC1 x CD16A BsAb)
Tumores sólidos
BGB-B2033
(GPC3 x 4-1BB BsAb)
Tumores sólidos
BG-T187†
(EGFR x MET TsAb)
Tumores sólidos
BG-C137†
(FGFR2b ADC)
Tumores sólidos
BGB-53038†
(PanKRAS inhibitor)
Tumores sólidos
BGB-58067†
(inibidor de PRMT5)
Tumores sólidos
BG-C477
(CEA ADC)
Tumores sólidos
A segurança e a eficácia não foram estabelecidas para produtos e/ou usos em investigação.
Programas de desenvolvimento – Hematologia
Medicamento
Indicação
Fase 1
Fase 2
Fase 3
Zanubrutinibe
(inibidor de BTK)
CLL/SLL
WM
R/R FL
R/R MZL
LCM VT
LCM R/R
LDGCB R/R com CD79B
Malignidades da célula B previamente tratadas
Sonrotoclax
(inibidor de BCL2)
LLCb VT
WM R/R
LLC R/R
LCM R/R
TN CLL/SLL †
MM com t(11;14) R/R
LMA/SMD
Malignidades da célula B
BGB-16673
(CDAC direcionado a BTK)
Malignidades da célula B
B-cell malignancies†
LCM R/R e LLC R/R
BGB-21447
(next gen BCL2 inhibitor)
Malignidades da célula B
Tislelizumabe
(PD-1 mAb)
R/R cHL
Ociperlimabe
(TIGIT mAb)
R/R DLBCL
Zanubrutinibe
(inibidor de BTK)
Nefropatia membranosa primária
Nefrite lúpica
BGB-45035
(IRAK4 CDAC)
Immunology & inflammation
Blinatumomabe5
(CD3 x CD19 BsAb)
Pediatric R/R BP-ALL
A segurança e a eficácia não foram estabelecidas para produtos e/ou usos em investigação.
aMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor.
bin combination with zanubrutinib.
†Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.
1Colaboração com a Ensem; a BeiGene tem os direitos globais.
2DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights.
3Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China.
4Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand.
5Amgen collaboration; BeiGene has development and commercialization rights in China.
1L, first line; 2L, second line; 3L, third line; 4-1BB, tumor necrosis factor receptor superfamily member 9; ADC, antibody-drug conjugate; AML, acute myeloid leukemia; BC, breast cancer; BCL2, B-cell lymphoma 2; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BsAb, bispecific antibody; BTC, biliary tract cancer; BTK, Bruton tyrosine kinase; CCR8, the C-C motif chemokine receptor 8; CD3, cluster of differentiation 3; CD16A, Fc receptor FcγRIIIa; CD19, cluster of differentiation 19; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; CDK2, cyclin-dependent kinase 2; CDK4, cyclin-dependent kinase 4; CEA, carcinoembryonic antigen; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; DGKζ, diacylglycerol kinase ζ; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; EGFR, epidermal growth factor receptor; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; FL, follicular lymphoma; gBRCAm, germline BReast CAncer gene (BRCA) mutation; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; GEJC, gastroesophageal junction carcinoma; GI, gastrointestinal; GPC3, glypican-3; IL-15, interleukin-15; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; IO, immunotherapy; IRAK4, interleukin-1 receptor-associated kinase 4; KRAS, Kirsten rat sarcoma virus; LA, locally advanced; mAb, monoclonal antibody; LAG3, lymphocyte activation gene 3; LS-SCLC, limited-stage small cell lung cancer; mAb, monoclonal antibody; MCL, mantle cell lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MDS, myelodysplastic syndromes; MM, multiple myeloma; MSS, microsatellite stability; MTx, maintenance treatment; MUC1, mucin 1; MZL, marginal zone lymphoma; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non–small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PRMT5, protein arginine methyltransferase 5; PSOC, platinum-sensitive ovarian cancer; R/R, recurrent/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; SMAC, second mitochondria-derived activator of caspase; STEAP1, six-transmembrane epithelial antigen of the prostate 1; Sq, squamous; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TN, treatment naive; TsAb, trispecific antibody; UBC, urothelial bladder cancer; UC, urothelial carcinoma; WM, Waldenström macroglobulinemia.
Pipeline clínico interativo
Vídeos
Mecanismo de ação do Anti-OX40
Mecanismo de ação de Anti-PD-1
Mecanismo de ação do inibidor de CDK4
Mecanismo de ação de BTKI
Mecanismo de ação de anti-TIGIT
Mecanismo de ação de PARPI
